Health Condition 1: A150- Tuberculosis of lung
Conditions
Interventions
Intervention1: Probiotic - Bacillus coagulans and First Line Anti TB Drugs: Bacillus coagulans 120 Million CFU 1 Tablet Twice daily for 2 months.
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Control I
Sponsors
Sri Siddhartha Medical college
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed Pulmonary TB patients, aged 18-65 years ( as per WHO diagnostic criteria) Written consent from the patient
Exclusion criteria
Exclusion criteria: Patients of Extrapulmonary TB Pregnant women Immunocompromised patients and patients on immunosuppresive agents Patients with comorbidities like cardiovascular diseases (Hypertension, Ischaemic heart diseases, Cardiomyopathies), Diabetes, gastrointestinal disease, liver malfunction, tumor, severe mental or psychological illness, or cognitive impairment The use of probiotic supplementation within the previous 2 months. No informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To analyse impact of probiotic supplementation on inflammatory biomarkers like CRP (C-reactive protein), ESR ( erythrocyte sedimentation rate), TLC( Total leucocyte count), NEU( neutrophil counts) , MPV( mean platelet volume) in intensive treatment phase of Tuberculosis.Timepoint: 2 time points Baseline and end of 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess role of probiotics in the duration of sputum culture conversion To assess effect of probiotics on gastric side-effects of anti-tuberculosis treatment To assess role of probiotics in overall clinical improvement for TB patients taking treatment.Timepoint: 2 time points Baseline and end of 2 months | — |
Countries
India
Contacts
Public ContactDr Sheeba Malik
Sri Siddhartha Medical College
Outcome results
None listed